This response disparity between CRC and other KRAS-mutant cancer types to allele-specific inhibitors of KRASG12C and KRASG12D raises the possibility that tissue-specific molecular events may underlie the mechanism of limited efficacy, which has not yet been clearly defined. This evidence concerns the gene KRAS and cancer.